Novant Health Cancer Institute
Forsyth Medical Center Winston-Salem, NC Chair, IRB and Co-Chair, Neuro-Oncology Council
Dr. Stieber is a graduate of the University of California, Berkeley and Loma Linda University Medical School. After completion of his Radiation Oncology residency at the Medical University of South Carolina, Charleston and a two-year fellowship at the Mayo Clinic, Jacksonville, he obtained his specialty board certification and joined the faculty of the Department of Radiation Oncology Wake Forest University at the level of Assistant Professor. He later moved to the Department of Radiation Oncology at the Novant Health Cancer Institute in Winston-Salem, NC. Dr. Stieber has spent his professional career involved primarily in Neuro-Oncology clinical care and research. He is a former member of the Neuro-Oncology Steering Committee of the RTOG (now NRG) and NABTT (now ABTC). He is an experienced investigator in Phase I-III clinical trials (NCI and industry) with co-authorships in high-impact journals including the Journal of Clinical Oncology, Lancet Oncology, JAMA and the New England Journal of Medicine. In addition to his clinical duties, he is the Chair of the IRB for Novant Health Greater Winston-Salem Market, the co-lead of Neuro-Oncology system-wide for Novant Health Cancer Institute, and the Radiation Oncology Department Section Chief for Novant Health Forsyth Medical Center.
1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980
2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.
3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680
4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)
5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997. https://www.jbc.org
6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org